Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes-Reference-Cited by-同舟云学术

Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes

Published:2016 Issue:2 Volume:239 Page:89-94
ISSN:0040-8727
Container-title:The Tohoku Journal of Experimental Medicine
language:en
Short-container-title:Tohoku J. Exp. Med.

Author:

Murakami Takaaki¹,Ueba Yoko¹,Shinoto Yuya²,Koga Yasutoshi³,Kaneda Daita⁴,Hatoko Tomonobu¹,Kato Tomoko¹,Yonemitsu Shin¹,Muro Seiji¹,Oki Shogo¹

Affiliation:

1. Department of Diabetes and Endocrinology, Osaka Red Cross Hospital

2. Department of Neurology, Osaka Red Cross Hospital

3. Department of Pediatrics and Child Health, Kurume University School of Medicine

4. Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

Publisher

Tohoku University Medical Press

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.jstage.jst.go.jp/article/tjem/239/2/239_89/_pdf

Reference21 articles.

1. Chavez, A.O., Molina-Carrion, M., Abdul-Ghani, M.A., Folli, F., Defronzo, R.A. & Tripathy, D. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care, 32, 1542-1546.

2. Chen, C., Cheung, B.M., Tso, A.W., Wang, Y., Law, L.S., Ong, K.L., Wat, N.M., Xu, A. & Lam, K.S. (2011) High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care, 34, 2113-2115.

3. Ciregia, F., Giusti, L., Ronci, M., Bugliani, M., Piga, I., Pieroni, L., Rossi, C., Marchetti, P., Urbani, A. & Lucacchini, A. (2015) Glucagon-like peptide 1 protects INS-1E mitochondria against palmitate-mediated beta-cell dysfunction: a proteomic study. Mol. Biosyst., 11, 1696-1707.

4. Fan, R., Li, X., Gu, X., Chan, J.C. & Xu, G. (2010) Exendin-4 protects pancreatic beta cells from human islet amyloid polypeptide-induced cell damage: potential involvement of AKT and mitochondria biogenesis. Diabetes Obes. Metab., 12, 815-824.

5. Fujita, Y., Ito, M., Kojima, T., Yatsuga, S., Koga, Y. & Tanaka, M. (2015) GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases. Mitochondrion, 20, 34-42.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast growth factor 21 as a candidate of a novel serum biomarker for mitochondrial diabetes;Journal of Diabetes Investigation;2023-05-29

2. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using 111In-exendin-4 SPECT/CT imaging and the perspective of mitochondrial involvements;Frontiers in Endocrinology;2022-09-29

3. Blood biomarkers for assessment of mitochondrial dysfunction: An expert review;Mitochondrion;2022-01

4. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes;Acta Diabetologica;2021-05-05

5. Regulation of diurnal energy balance by mitokines;Cellular and Molecular Life Sciences;2021-01-19